Press Releases

Printer Friendly Version View printer-friendly version
<< Back
Implant Sciences Sells QS-B220 to Air Freight Atlanta
Builds Momentum in Sales to Freight Forwarders for Air Cargo Screening

WILMINGTON, MA -- (Marketwired) -- 06/11/13 -- Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has sold its TSA-approved Quantum Sniffer™ QS-B220 desktop explosives trace detector to Air Freight Atlanta. Air Freight Atlanta is a TSA Certified Cargo Screening Facility and will use the QS-B220 in an air cargo environment.

"Being a Certified Cargo Screening Facility, we require equipment that will help us effectively, securely, and rapidly scan cargo, while complying with all TSA requirements. When we were in the market to replace our aging ETD system, we witnessed a demonstration of the QS-B220. We were very impressed by the system's capabilities, ease-of-use, and low maintenance and consumables costs," stated Joe Jones of Air Freight Atlanta. "The performance of the QS-B220 far surpasses our former ETD systems, and comes with a much lower cost of ownership!"

"Our technology, which truly is the new standard in trace detection, continues to be recognized by freight forwarders for its operational advantages," commented Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones. "The needs of air cargo screening facilities were one of our prime considerations when we built the QS-B220. It's exciting to see our ideas validated by the industry."

About the Quantum Sniffer™ QS-B220 Desktop Explosives Trace Detector
The Quantum Sniffer QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:

Implant Sciences Corporation
Company Contact:
Glenn Bolduc
CEO
978-752-1700
Email Contact

or

Investor Contact:
Laurel Moody
646-810-0608
Email Contact

Source: Implant Sciences Corporation